#USA #Class Action #San Francisco #FTC Lawsuit #Hims & Hers

Hims & Hers Health Under Legal Scrutiny

Hims & Hers Health, Inc. (NYSE: HIMS) has recently come under fire as the company faces a securities class action lawsuit stemming from claims made by the Federal Trade Commission (FTC). The lawsuit, which alleges serious misconduct on part of the company, raises significant concerns about the integrity of its business practices and data protection policies.

Background of the Lawsuit

Hagens Berman, the law firm actively investigating claims against Hims, has urged investors who have incurred considerable losses to take action before the approaching deadline of November 2, 2026. The class period for the lawsuit spans from August 4, 2025, to July 29, 2026, during which the company's actions have been scrutinized, particularly in light of allegations related to deceptive practices concerning health information and subscription billing.

Key Allegations Against Hims

The lawsuit specifically targets several aspects of Hims' operations, focusing on the management of consumer health data and the company's billing practices. The FTC alleges that Hims made misleading statements about their policies protecting sensitive information. Notably, the complaint highlights the following issues:

1. Unapproved Sharing of Health Information: The allegations state that Hims shared patients' health data with third-party advertising platforms, including major companies such as Meta (Facebook) and Snap. This breach of consumer trust is particularly alarming, especially considering Hims' marketing claims of strict privacy and data protection.

2. Improper Subscription Billing: Hims is accused of violating the Restore Online Shoppers’ Confidence Act (ROSCA) by enrolling customers in recurring subscription billing without proper consent. Customers reportedly found themselves charged for prescriptions almost immediately after submitting intake forms, without adequate consultation from medical providers, raising significant ethical and regulatory concerns.

3. Lack of Transparency: The company's practices may have involved hidden cancellation options, making it difficult for consumers to terminate their subscriptions efficiently. This kind of consumer manipulation, often referred to as "dark patterns," has drawn regulatory attention and public backlash.

The Impact of Legal Actions on Hims' Stock

The fallout from these allegations was immediate and severe. Following the announcement of the FTC's complaint on July 29, 2026, Hims' stock plummeted by $4.32, equivalent to a staggering 14.7% drop. This decline resulted in a loss of over $970 million in market capitalization in a single trading day, raising alarm bells among investors and stakeholders.

Hagens Berman partner Reed Kathrein stated that their investigation is primarily concerned with whether Hims had intentionally misled investors about its operational practices, especially regarding the adequacy of its internal controls and the potential financial consequences of the alleged misconduct.

Next Steps for Affected Investors

For Hims investors who believe they have suffered substantial losses, now is a critical time to get involved. Hagens Berman encourages individuals to submit their losses or any pertinent information regarding the company to aid in the investigation. Additionally, the firm advises whistleblowers with insider information about Hims to consider participating in the SEC Whistleblower program, whereby they could receive financial rewards for their contributions.

Conclusion

In conclusion, as Hims & Hers Health navigates serious legal challenges, affected investors must act promptly to safeguard their interests. The upcoming deadline of November 2, 2026, is a pivotal moment for those who have invested in HIMS during the tumultuous period outlined in the class action suit. Staying informed and proactive can help mitigate potential losses during this uncertain period for the company.